EssilorLuxottica and GrandVision enter into an agreementwith Vision Group for the sale of stores in Italy Charenton-le-Pont, France, Schiphol, The…
Exclusive rights for a novel early-stage asset acquired from Genoscience Pharma in cholangiocarcinoma in the United States, Canada and EuropePhase…
Phase 1 study in patients with advanced solid tumors planned to start in the first quarter of 2022Ad hoc announcement…
GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis,…
Access to AlenuraTM, a dual mode-of-action advanced clinical candidate for the treatment of acute pain in interstitial cystitis/bladder pain syndrome…
-European Commission Decision Anticipated in Q1 2022- -CHMP recommendation follows the recent acceptance of the linzagolix uterine fibroids NDA by…
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 17, 2021 – Addex Therapeutics Ltd (SIX: ADXN and…
CEO Ian Crosbie to participate in a panel discussion on “MedTech and digital tools: What is the Mindset for 2022?”GHENT, Belgium,…
MARKHAM, Ontario, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has…
NEW HAVEN, Conn., Dec. 16, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical…